Vitamin C Cancer Controversy Reignites: The Key Is Not Supplements, but High-Dose Intravenous Administration

Whether vitamin C can fight cancer was once one of the fiercest controversies in the history of modern medicine. What is now receiving renewed research attention is not the vitamin tablets found in pharmacies, but “pharmacologic-dose ascorbate,” administered by intravenous infusion to achieve extremely high concentrations in the blood. It is closer to an experimental drug and must be evaluated in combination with standard treatment.

This distinction explains why some early studies produced conflicting results. Nobel laureate Linus Pauling and physician Ewan Cameron once argued that vitamin C could help cancer patients, but subsequent clinical trials using oral capsules did not confirm a benefit. Later pharmacokinetic studies showed that the intestines limit oral absorption, while intravenous administration can produce concentrations in the blood and tissues that oral dosing cannot achieve. The two routes therefore do not, in practice, test the same biological effect.

At high concentrations, ascorbate may shift from an everyday nutrient into a substance that promotes oxidative reactions, increasing the oxidative stress borne by cancer cells. Some tumor cells, because of their metabolic state and weaker antioxidant defenses, may be more susceptible to damage and become sensitive to chemotherapy. However, this vulnerability is not shared by all cancer cells, and vitamin C cannot therefore be regarded as a universally applicable anticancer drug.

The most closely watched clinical signal comes from a Phase 2 randomized trial at the University of Iowa. The study enrolled 36 patients with stage IV pancreatic cancer, of whom 34 were assigned to treatment. In addition to gemcitabine and nab-paclitaxel, the experimental group received intravenous infusions of 75 grams of ascorbate three times a week. The study reported that median overall survival increased from 8.3 months in the chemotherapy group to 16 months, while median progression-free survival increased from 3.9 months to 6.2 months.

The researchers found no increase in the frequency or severity of adverse events after intravenous vitamin C was added, and quality of life did not appear to be impaired. The university separately stated that some patients appeared better able to tolerate chemotherapy. However, the trial was very small and was terminated early, and the survival difference may have been affected by sample variability. Larger Phase 3 studies are still needed to confirm whether the efficacy is robust and which patients are most likely to benefit.

The US National Cancer Institute describes the existing evidence as promising but limited. High-dose intravenous vitamin C has not been approved by the US Food and Drug Administration to treat cancer and cannot replace surgery, chemotherapy, or other standard therapies. Patients with kidney disease or glucose-6-phosphate dehydrogenase deficiency may also face significant risks. What this wave of research truly revises is the scientific question represented by the route of administration and dosage, not the anticancer reputation of oral vitamin supplements.